In the same way as pharmaceutical companies must apply foralicence to sell adrug after extensive testing, so suppliers of legal highs will be able to market products in New Zealand if they can demonstrate they present a low risk of harm.
It's decision to approve the drugfor use with some NHS patients follows the granting of a UK licencefor its use, along with standard chemotherapy, to treat the aggressive form of non-Hodgkin's lymphoma.